5 days ago
PRAX Investors Have Opportunity to Join Praxis Precision Medicines, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Praxis Precision Medicines, Inc. ('Praxis' or 'the Company') (NASDAQ: PRAX) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Praxis announced its Q2 2025 financial results on August 4, 2025. The Company reported mid-state clinical results from the trial of vormatrigine, an anti-seizure medication. The Company admitted that more than half of patients experienced treatment-emergent adverse events, with almost 25% of study participants discontinuing the medication. Based on this news, shares of Praxis fell more than 5% on the same day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
